Duration of Reduced CA19-9 Levels Is a Better Prognostic Factor Than Its Rate of Reduction for Unresectable Locally Advanced Pancreatic Cancer.
CA 19-9
pancreatic cancer
prognostic factor
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Aug 2021
22 Aug 2021
Historique:
received:
23
07
2021
revised:
16
08
2021
accepted:
20
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
A decrease in carbohydrate antigen (CA) 19-9 levels has been proposed as a prognostic marker for survival and recurrence in patients with pancreatic cancer. We evaluated the association between duration of reduced CA 19-9 levels during 6 months after treatment and long-term survival for 79 patients with unresectable locally advanced pancreatic cancer (LAPC). We calculated the differences between pretreatment and monthly CA19-9 levels. We categorized 71 patients with decreases in CA19-9 levels into three groups based on the duration of these reduced levels (>2, >3, and >4 months). The cut-off level for long-term (more than 2 years) survival was identified as a 44% reduction from the baseline, using a ROC curve. A reduction duration >2 months was not associated with overall survival (
Identifiants
pubmed: 34439377
pii: cancers13164224
doi: 10.3390/cancers13164224
pmc: PMC8391823
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Sci Rep. 2019 Nov 7;9(1):16187
pubmed: 31700023
CA Cancer J Clin. 2013 Sep;63(5):318-48
pubmed: 23856911
Oncology. 2008;75(1-2):120-6
pubmed: 18784438
Cancer Res. 1987 Oct 15;47(20):5501-3
pubmed: 3308077
Cancers (Basel). 2019 Feb 26;11(3):
pubmed: 30813624
Br J Cancer. 2017 Jun 6;116(12):1544-1550
pubmed: 28472821
Ann Surg Oncol. 2014 Dec;21(13):4351-8
pubmed: 25092157
HPB (Oxford). 2015 Oct;17(10):942-52
pubmed: 26255895
J Gastroenterol Hepatol. 2016 Feb;31(2):506-12
pubmed: 26250642
Oncologist. 2020 Oct;25(10):859-866
pubmed: 32277842
Oncology. 2006;70(4):255-64
pubmed: 16899980
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ann Surg. 2019 Jun;269(6):1154-1162
pubmed: 31082915
Lancet Oncol. 2008 Feb;9(2):132-8
pubmed: 18249033
J Clin Med. 2020 May 14;9(5):
pubmed: 32423123
Ann Surg. 2021 Feb 1;273(2):341-349
pubmed: 30946090
J Hepatobiliary Pancreat Sci. 2013 Aug;20(6):590-600
pubmed: 23660962
J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061
pubmed: 28784865
World J Gastroenterol. 2014 Aug 21;20(31):10740-51
pubmed: 25152577
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Cancer Lett. 2016 Jun 1;375(2):231-237
pubmed: 26970276
Br J Cancer. 2004 Aug 16;91(4):673-7
pubmed: 15226765
Cancer Chemother Pharmacol. 2020 Apr;85(4):641-650
pubmed: 32157412
Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):119-25
pubmed: 20605363
Cancer Med. 2020 Jul;9(13):4711-4723
pubmed: 32415696
World J Gastroenterol. 2013 Nov 14;19(42):7461-71
pubmed: 24259979
Ann Surg. 2021 Jan 1;273(1):154-162
pubmed: 30921051
HPB (Oxford). 2014 May;16(5):430-8
pubmed: 23991810
Ann Surg Oncol. 2014 May;21(5):1530-7
pubmed: 24473642
Ann Surg. 2018 Aug;268(2):215-222
pubmed: 29462005